Human Immunology News Volume 10.27 | Jul 12 2022

    By
    Danielle Corrigan
    -
    0
    39








    2022-07-12 | HIN 10.27


    Human Immunology News by STEMCELL Technologies
    Vol. 10.27 – 12 July, 2022
    TOP STORY

    Super-Enhancer Hypermutation Alters Oncogene Expression in B Cell Lymphoma

    Researchers showed that active super-enhancers were highly and specifically hypermutated in 92% of samples from individuals with diffuse large B cell lymphoma, displayed signatures of activation-induced cytidine deaminase activity, and were linked to genes that encoded B cell developmental regulators.
    [Nature]

    Abstract

    Explore tools and resources for your return to the lab
    PUBLICATIONSRanked by the impact factor of the journal

    Dissecting the Treatment-Naive Ecosystem of Human Melanoma Brain Metastasis

    The authors performed single-cell/nucleus RNA-seq in 22 treatment-naive melanoma brain metastasis and 10 extracranial melanoma metastases and matched spatial single-cell transcriptomics and T cell receptor-seq.
    [Cell]

    AbstractFull Article

    Functional Landscapes of POLE and POLD1 Mutations in Checkpoint Blockade-Dependent Antitumor Immunity

    Patients with POLE/POLD1 mutated tumors harboring telltale mutational signatures responded better to immune checkpoint blockade therapy than patients harboring wild-type or signature-negative tumors.
    [Nature Genetics]

    Abstract

    Systematic Discovery and Perturbation of Regulatory Genes in Human T Cells Reveals the Architecture of Immune Networks

    Researchers developed an approach for systematic discovery of upstream regulators of critical immune factors — IL2RA, IL-2 and CTLA4 — in primary human T cells.
    [Nature Genetics]

    Abstract

    Autologous T Cell Responses to Primary Human Colorectal Cancer Spheroids Are Enhanced by Ectonucleotidase Inhibition

    Investigators showed the increased expression of CD39, and its co-expression with PD-1, on tumor infiltrating T cells compared with mucosal lymphocytes.
    [Gut]

    Abstract

    Human Complete NFAT1 Deficiency Causes a Triad of Joint Contractures, Osteochondromas, and B Cell Malignancy

    Scientists reported the first human identified with complete deficiency of nuclear factor of activated T cells 1 (NFAT1).
    [Blood]

    Abstract

    Pathogenic Neuropsychiatric Effect of Stress-Induced Microglial Interleukin 12/23 Axis in Systemic Lupus Erythematosus

    The authors investigated stress effects on the neuropsychiatric pathophysiology in systemic lupus erythematosus using lupus-prone mice and patient data.
    [Annals of the Rheumatic Diseases]

    AbstractPress Release

    NAD+ Salvage Governs Mitochondrial Metabolism Invigorating NK Cell Anti-Tumor Immunity

    Researchers identified NAD+ metabolism as a central hub to determine the homeostasis and function of NK cells.
    [Hepatology]

    Abstract

    Interrogating Glioma-M2 Macrophage Interactions Identifies Gal-9/Tim-3 as a Viable Target against PTEN-Null Glioblastoma

    Scientists showed that PTEN deficiency induced a symbiotic glioma-M2 macrophage interaction to support glioma progression.
    [Science Advances]

    Full Article

    Human CD38 Regulates B Cell Antigen Receptor Dynamic Organization in Normal and Malignant B Cells

    The authors showed that targeting CD38 with an antibody, or removing this molecule with CRISPR/Cas9, inhibited the association of CD19 with the IgM-B cell receptor (BCR), impairing BCR signaling in normal and malignant B cells.
    [Journal of Experimental Medicine]

    Abstract

    Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Anti-Tumor Cytotoxicity against Neuroblastoma

    Hu14.18-IL15 and Hu14.18-IL21 exhibited robust preclinical activity, warranting further consideration for clinical testing in patients with GD2-expressing neuroblastoma.
    [Clinical Cancer Research]

    Abstract

    Glucose Metabolism Controls Human γδ T Cell-Mediated Tumor Immunosurveillance in Diabetes

    Scientists showed that high glucose-induced Warburg effect type of bioenergetic profile in Vγ9Vδ2 T cells, leading to excessive lactate accumulation, which further inhibited lytic granule secretion by impairing the trafficking of cytolytic machinery to the Vγ9Vδ2 T cell-tumor synapse.
    [Cellular & Molecular Immunology]

    Abstract

    Neuromedin U Promotes Human Type 2 Immune Responses

    Researchers investigated the expression of neuromedin U (NmU) in human blood and airways, and the expression of NmU receptors by human immune cells in blood and lung tissue.
    [Mucosal Immunology]

    Full Article

    Request your free copy of the 'Frequencies of Cell Types in Human Peripheral Blood' Wallchart
    REVIEWS

    Targeting TFH Cells in Human Diseases and Vaccination: Rationale and Practice

    TFH cells are essential in sustaining protective antibody responses necessary for pathogen clearance in infection and vaccine-mediated protection. Conversely, aberrant and excessive TFH cell responses mediate and sustain pathogenic antibodies to autoantigens, alloantigens, and allergens.
    [Nature Immunology]

    Abstract

    An Unexplored Angle: T Cell Antigen Discoveries Reveal a Marginal Contribution of Proteasome Splicing to the Immunogenic MHC Class I Antigen Pool

    The authors explain the significance of knowing the contribution of spliced peptides for accurate analyses of peptidomes on one hand, and to serve as a potential source of targetable tumor antigens on the other hand.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Full Article

    Application of ATAC-Seq in Tumor-Specific T Cell Exhaustion

    Scientists review the latest developments, which provide a clearer molecular understanding of T cell exhaustion, reveal potential new therapeutic targets for persistent viral infection and cancer, and provide new insights for designing effective immunotherapy for treating cancer and chronic infection.
    [Cancer Gene Therapy]

    Full Article

    INDUSTRY AND POLICY NEWS

    Vertex Absorbs ViaCyte and Its Stem Cell-Based Diabetes Treatment for $320M, Clearing Out Competition

    Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million.
    [Fierce Biotech]

    Press Release

    Elixiron Immunotherapeutics Receives Grant From the Alzheimer’s Association to Trial Microglia-Targeting Immunotherapy

    Elixiron Immunotherapeutics, a clinical stage drug development company announced that it has received a new grant from the Alzheimer’s Association Part the Cloud program to accelerate the application of EI-1071, a novel orally-administered immunomodulatory therapy for people with Alzheimer’s disease.
    [Elixiron Immunotherapeutics (Globe Newswire, Inc.)]

    Press Release

    FEATURED EVENT

    Till & McCulloch Meetings

    October 3 – 5, 2022
    Vancouver, British Columbia, Canada

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researcher – Translational Vascular Biology

    University Hospital of Muenster – Münster, Germany

    Postdoctoral Position – T Cell Development

    Icahn School of Medicine at Mount Sinai – New York, New York, United States

    Postdoctoral Fellows – Bioinformatics

    Memorial Sloan Kettering Cancer Center – New York, New York, United States

    Postdoctoral Fellow – Thoracic Malignancies

    Baylor College of Medicine – Houston, Texas, United States

    Associate Professor – Thematic Research Programs

    The Chinese University of Hong Kong – Hong Kong, China

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Human Immunology News Twitter